Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fiscal Cliff Legislation Adjusts ESRD Payment Bundle To Help Offset Doc Fix

This article was originally published in The Pink Sheet Daily

Executive Summary

In legislation passed by both chambers of Congress Jan. 1, the cost of a one-year reprieve from sharp cuts to Medicare physician payments, scheduled to begin in 2013, would be offset by a reduction in Medicare’s bundled payment for end-stage renal disease. The reduced payment would take into account a drop in the use of erythropoiesis-stimulating agents observed over the last several years.

You may also be interested in...



Budget Bill Makes End Run Around Medicare Payment Policy For Omidria, Amyvid

Surprise provision directs favorable Medicare Part B reimbursement for a handful of therapeutics beginning later this year.

Reimbursement Briefs: ESRD Drugs, Medicare Data, Rx Adherence, Cancer Drug Value

Physician patch bill delays including oral ESRD drugs in bundled Medicare payments until 2024; ASCO working on method to score relative value of cancer drugs, and more news in brief.

Epogen Use Re-Calculation Drives 9.4% Medicare ESRD Bundled Payment Cut In 2014

CMS was directed by the American Taxpayer Relief Act to “rebase” the ESRD payment level by re-calculating the use of erythropoiesis-stimulating agents and other infused or injectable therapies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074785

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel